GovChime
Notice ID: 11adaa7ee815481cbd728394b39199f5Combined Synopsis/Solicitation

Compounds synthesis for NCATS ETB probe portal

Archived on September 29, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM UTC−04:00
Posted
September 8, 2020
Notice type
Combined Synopsis/Solicitation
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
325998: All Other Miscellaneous Chemical Product and Preparation Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIDA
Last updated
Apr 29, 2026

Identifiers

Solicitation number
75N95020Q00320
Notice ID
11adaa7ee815481cbd728394b39199f5

Description

COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: Compounds synthesis for NCATS ETB probe portal (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95020Q00320 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures; FAR Subpart 13.5 Simplified Procedures for Certain Commercial Items; and FAR Part 12 Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2020-07, dated 08/31/2020. (iv) The associated NAICS code 325998 and the small business size standard is 500 employees. This requirement is a total small-business set aside. Offers from Other than Small Businesses will not be considered. (v) Project Requirements: The Government is seeking to acquire the following seventeen (17) synthesized compounds: ML001 (100mg) ML026 (100mg) ML059 (100mg) ML063 (100mg) ML091 (100mg) ML103 (100mg) ML105 (100mg) ML149 (100mg) ML196 (100mg) ML200 (100mg) ML220 (100mg) ML227 (100mg) ML238 (100mg) ML247 (100mg) ML251 (100mg) ML267 (100mg) ML285 (100mg) The following requirements must be met: Purity >95% for each compound NMR, hi-res mass spec included for each compound CoA and SDS included for each compound Additionally, total shipping price must be included in each offerors quote. (vi) Delivery/Inspection: Offerors shall provide on their quote a good faith delivery estimate from receipt of an order. The Government anticipates a several week lead time to synthesize these compounds, however lead times in excess of twelve 12 weeks will not be accepted. Partial shipments are acceptable. Delivery, inspection, and acceptance will be performed at NCATS located at 9800 Medical Center Drive, Rockville, MD 20852. (vii) The provision at FAR clause 52.212-1, Instructions to Offerors Commercial Items, applies to this acquisition. (viii) The provision at FAR clause 52.212-2, Evaluation Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation is the lowest-priced, technically acceptable offer. (ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications Commercial Items, with its offer. (x) The FAR clause at 52.212-4, Contract Terms and Conditions Commercial Items, applies to this acquisition. The following FAR provisions or clauses are incorporated by reference: 52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-16, Commercial and Entity Code Reporting (Jul 2016) 52.204-18, Commercial and Entity Code Maintenance (Jul 2016) 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services of Equipment HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015). 52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014). (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items, applies to this acquisition (xii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiii) The offeror must complete and return FAR 52.204-24 with its offer. (xiv) Responses to this solicitation must include sufficient information to establish the interested parties bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by September 14, 2020, 9:00 am, Eastern Standard Time and reference number 75N95020Q00320. Responses shall be submitted electronically to Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov. Fax responses will not be accepted. (xv) The name of the individual to contact for information regarding the solicitation: Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75N95020Q00320
  1. Combined Synopsis
  1. Combined SynopsisCurrentSep 8, 2020

    Compounds synthesis for NCATS ETB probe portal

    Notice 11adaa7ee815481cbd728394b39199f5 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Takeda Pharmaceutical Company Limited. The National Institutes of Health (NIH) Clinical Center (CC) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. This includes the purchase of Gammagard S/D 10gm and Gammagard S/D 5gm kits. The NIH CC Pharmacy is requesting the purchase of 10 bottles each of Gammagard S/D 10gm and Gammagard S/D 5gm kits and as needed to provide anticipated current patient care need. Justification: TAKEDA Group is the only responsible source for Gammagard S/D. There are multiple patients in the NIH currently on therapy with Gammagard S/D and additional patients may be transferred to the NIH for evaluation and treatment. Gammagard S/D is on the Clinical Center’s formulary, requiring a supply to be available in the Pharmacy Department at all times to support ongoing patient care. The NIH needs to keep using the same items to keep treatment consistent.
45%
Pre-Solicitation11/16/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
45%
Pre-Solicitation11/11/2026
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
45%
Combined Synopsis11/04/2026
Naval Surface Warfare Center Indian Head Division (NSWC IHD), located in Indian Head, Maryland, is interested in establishing Blanket Purchase Agreements (BPAs) with companies that provide standard commercial supplies and services at competitive prices in Classification: PSC/FSC Code 6525, NAICS 325992, X-RAY EQ SUPPLIES Below is some of the items that we will be procuring: Radiographic Film Below is our current requirement but, however are requirement could change as needed:. Carestream T200 14x17 NIF (6549463) Carestream MX125 14x17 NIF (6549455) AGFA D5 14x17 NIF (LHVLU) AGFA D4 14x17 NIF (LHQ9N) Radiographic Processing Chemicals The below chemicals are utilized in the processing of X-ray film Agfa G135 Industrial X Ray Developer Replenisher Kit Agfa G335 Industrial X Ray Fixer Kit Agfa RP Developer Starter Clear Image Radiographic Cleaner BPA Calls will not exceed the Simplified Acquisition Threshold and Offerors will compete at the call level. Interested companies must (have/include): Cover sheet with the official company name, cage code, and point of contact including name, phone number, and email address. Documentation addressing the capabilities and expertise. Complete and return a price list, if applicable. BPA's will be awarded on the basis of positive Past Performance. Interested vendors should provide a minimum of three Past Performance References (attached). The Past Performance references shall include name of the business/organization, address, and contract /order number, and award amount, point of contact, telephone number and description of the item. The Past Performance will be evaluated based upon Customer Satisfaction, Timeliness, Technical Success, Program Management, and Quality. The government reserves the right to use additional references if available. An active account in the Procurement Integrated Enterprise Environment (PIEE formerly WAWF) at https://pieef.eb.mil to enter invoices and receiving reports, or credit card as a method of payment. An active account in System for Award Management (SAM https://www.sam.gov) Important Notes: *This is a small business set-aside. If you possess a GSA contract, please note your GSA contract number in your response. *Vendors who are found to have technical and past performance merit will be issued a Master BPA to be able to bid on future requirements. *Price lists and catalog prices can be provided as they may help with direct award under the $10k threshold. UPATED 9/30/2024 The Government is updating the required submission deadlines and changing the award dates. The following are the new guidelines: The Government intends to issue Master BPAs on a 6-month rotation through June 2029. To be considered for a June award, Interested Vendors should provide documentation and references to my email, rebecca.m.collins17.civ@us.navy.mil, no later than 30 April. For a December award, interested vendors should provide documentation and references by email to rebecca.m.collins17.civ@us.navy.mil no later than 31 October. PREVIOUS DATES *The Government intends to issue Master BPAs on 6 month rotation through February 2029. To be considered for a February award, interested vendors should provide documentation and references to by email to rebecca.m.collins17.civ@us.navy.mil no later than 31 December. For an August award, interested vendors should provide documentation and references by email to rebecca.m.collins17.civ@us.navy.mil no later than 30 June. *The Government reserves the right to consider past performance information available from other sources, including, but not limited to, information in the Contractor Performance Assessment Reporting System (CPARS), the Past Performance Information Retrieval System (PPIRS https://www.ppirs.gov), and the Federal Awardee Performance and Integrity Information System (FAPIIS). The Points of Contact for this request are: Rebecca Collins- rebecca.m.collins17.civ@us.navy.mil Brandi Sorzano – brandi.l.sorzano.civ@us.navy.mil TPOC/TAS – (Lynn Tarburton) – lynn.m.tarburton.civ@us.navy.mil **Attachments** All announcements should include 3 Past Performance Reference. (Sheet attached). X-ray film will have a separate attachment documenting requirements. ***AMENDMENT 0001*** At this time, IHD is pausing the rolling admissions process for additional BPA vendors. If your company submitted a package for evaluation, when the rolling admissions process is reopened, your company will be afforded an opportunity to submit a new package or resend your prior package for consideration. Our IHD team is exploring opportunities to automate the BPA interest and evaluation process. We look forward to sharing the new process enhancements with you in the future. Please do not contact the individuals listed below regarding the BPA status or process at this time. Our IHD_BPA@us.navy.mil inbox will be used for all future inquiries.
44%
Combined Synopsis11/11/2028
FY27 request for microbiology testing media for Seattle Division Microbiology Department. These products are required for the identification of pathogenic organisms. This includes products formatted to maintain a long shelf-life, such as Oxidase, Indole and Acridine Orange that are used daily and are critical for organism identification, as well as perishable selective agar, biochemical test kits and other required products such as ATCC organisms, mandated by the College of American Pathologists (CAP), as part of our Quality Control for media. Products are ordered for weekly delivery or as needed, and these supplies enable microbiologists to identify diseases in veteran patients.
43%
Market Research11/10/2026

Additional Details

Solicitation Number

75N95020Q00320

Archive Date

Sep 29, 2020

Office Address

Bethesda, MD, 20892